Search | IOVS | ARVO Journals

Showing 1 – 20 of 45

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

C-Reactive protein levels and the Outer retina in a large cohort study: UK Biobank

Sharon Yu Lin Chua; Paul J Foster; Andrew J Lotery; Tariq Aslam; Charles A Reisman; Tunde Peto; Catherine A Egan; Baljean Dhillon; Praveen J Patel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2313. doi:

ARVO Annual Meeting Abstract June 2020

Real world outcomes for aflibercept in diabetic macula edema

Haralabos Eleftheriadis; Irene Mary Stratton; James S Talks; Peter Henry Scanlon; Shahram Kashani; Andrew J Lotery; Clare Bailey; Raj Mukherjee; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3290. doi:

ARVO Annual Meeting Abstract June 2020

Phenome-wide association analysis on risk variants for age-related macular degeneration reveals shared genetic influences with a wide range of disorders: the Million Veteran Program

Robert Igo; Tyler G Kinzy; Christopher W. Halladay; Dana C. Crawford; Paul B Greenberg; Jack M. Sullivan; Steven J. Fliesler; Wen-Chih Wu; Helene Choquet; Karina Patasova; Eric Jorgenson; Pirro G Hysi; Andrew J Lotery; Jessica Cooke Bailey; Neal S. Peachey; Sudha K Iyengar

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3518. doi:

ARVO Annual Meeting Abstract June 2020

Implementing digital applications for self-monitoring of visual function in the MONARCH study: technological and practical challenges.

Ruth E Hogg; Robin Wickens; Charlene Treanor; Abby O'Connell; Lucy Culliford; Chris Rogers; Eleanor Gidman; Tunde Peto; Paul C Knox; Ben Burton; Andrew J Lotery; Sobha Sivaprasad; Michael Donnelly; Barney Reeves

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3079. doi:

Genetics June 2020

Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma Levels Resulting in Increased Risk of Age-Related Macular Degeneration

PDF

Thomas M. Hallam; Kevin J. Marchbank; Claire L. Harris; Clive Osmond; Victoria G. Shuttleworth; Helen Griffiths; Angela J. Cree; David Kavanagh; Andrew J. Lotery
TAGS: age-related macular degeneration, cohort studies, complement factor i, cultural formulation interview, fibrinogen, genetics, plasma, regression analysis, genetic analysis
Invest. Ophthalmol. Vis. Sci.. 2020; 61(6):18. doi: https://doi.org/10.1167/iovs.61.6.18

Includes: Supplemental Content

Clinical and Epidemiologic Research May 2020

Ambient Air Pollution Associations with Retinal Morphology in the UK Biobank

PDF

Sharon Y. L. Chua; Anthony P. Khawaja; Andrew D. Dick; James Morgan; Baljean Dhillon; Andrew J. Lotery; Nicholas G. Strouthidis; Charles Reisman; Tunde Peto; Peng T. Khaw; Paul J. Foster; Praveen J. Patel; on behalf of The UK Biobank Eye and Vision Consortium
TAGS: air pollution, biobanks, language morphology, morphology
Invest. Ophthalmol. Vis. Sci.. 2020; 61(5):32. doi: https://doi.org/10.1167/iovs.61.5.32

ARVO Annual Meeting Abstract June 2017

Long-term Outcome of Bevacizumab Therapy in Sorsby Fundus Dystrophy, A Case Series.

Rebecca Kaye; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):229. doi:

ARVO Annual Meeting Abstract June 2017

UK Multi-centre Medisoft EMR audit of intra-operative pressure event following implant of ILUVIEN ® (fluocinolone acetonide 190 μg).

Fahd Quhill; Clare Bailey; Usha Chakravarthy; Andrew J Lotery; Geeta Menon; James Talks

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4622. doi:

ARVO Annual Meeting Abstract June 2017

The impact of prior steroid therapy on safety outcomes following treatment with ILUVIEN (fluocinolone acetonide) – An analysis of intra-ocular outcomes (IOP) from UK electronic medical records.

Serena Salvatore; Clare Bailey; Usha Chakravarthy; Andrew J Lotery; Geeta Menon; James Talks

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4631. doi:

ARVO Annual Meeting Abstract June 2017

Twelve-Month Outcomes of Aflibercept vs. Ranibizumab for Wet Macular Degeneration

Hussein Almuhtaseb; Luke Michaels; Thanos Vardarinos; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):431. doi:

ARVO Annual Meeting Abstract June 2017

Twenty Four-Month Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration: Different Treatment Regimens in Year Two based on the Macular Status at the End of Year One

Luke Michaels; Hussein Almuhtaseb; Adham Youssef; Christina A Rennie; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):433. doi:

ARVO Annual Meeting Abstract June 2017

Identification of a Novel Variant Associated with anti-VEGF Response in Age-related Macular Degeneration Using Exome Chip Analysis

Michelle Grunin; Laura Lorés-Motta; Moeen Riaz; Jordi Corominas; Andrea J. Richardson; Sascha Fauser; Robyn H Guymer; Eiko de Jong; Iris M Heid; Carel C B Hoyng; Andrew J Lotery; Paul Mitchell; Paul N Baird; Anneke I Den Hollander; Itay Chowers

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1840. doi:

ARVO Annual Meeting Abstract June 2017

The myocilin GLN368Stop mutation in normal tension glaucoma

Carly Lewis; Jason Kam; Todd E Scheetz; Ben R Roos; Edwin M Stone; Cheryl Khanna; Kazuhide Kawase; Robert Ritch; Andrew J Lotery; Sobha Sivaprasad; Jessica Cooke Bailey; Louis R Pasquale; Janey L. Wiggs; Young H Kwon; Wallace L M Alward; John Fingert

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2127. doi:

ARVO Annual Meeting Abstract June 2017

Hydroxyapatite induced experimental retinal degeneration in a murine model

Elena Pipi; Paul Ibbett; Andrew J Lotery; Imre Lengyel; V. Hugh Perry; Jessica Teeling

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2272. doi:

ARVO Annual Meeting Abstract June 2017

Murine Retinal Development, Morphology and Function in Albinism: Potential Implications for Therapeutic Development

Helena helenalee100@yahoo.co.uk Lee; Jennifer Scott; Helen Griffiths; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5570. doi:

ARVO Annual Meeting Abstract September 2016

One year visual and anatomic outcomes in eyes receiving aflibercept according to a fixed-interval dosing (Q8W) for neovascular age-related macular degeneration.

Osama Kanavati; Hussein Almuhtaseb; Georgios I Agorogiannis; Srini Goverdhan; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):517. doi:

ARVO Annual Meeting Abstract September 2016

2nd Year Visual Acuity Outcomes of AMD patients treated with Aflibercept : Data Analysis from the UK Aflibercept users group

Hussein Almuhtaseb; James S Talks; Rob Johnston; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):545. doi:

ARVO Annual Meeting Abstract September 2016

Long term vision results following retinal gene therapy for choroideremia

Robert E MacLaren; Thomas L Edwards; Jasleen Jolly; Alun R Barnard; Kanmin Xue; Susan Downes; Graham E Holder; Graeme C.M. Black; Andrew J Lotery; Andrew Webster; Miguel Seabra

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Real-life outcomes of switching AntiVEGF treatment from ranibizumab to aflibercept for neovascular agerelated macular degeneration (nAMD): UK multicentre study.

Faruque Daudbhai Ghanchi; Nishal Patel; James S Talks; Andrew J Lotery; Sobha Sivaprasad; Clare Bailey; Rob Johnston; Martin McKibbin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3334. doi:

ARVO Annual Meeting Abstract September 2016

A systematic review to assess the “Treat-and-Extend” dosing regimen compared to monthly and as-needed dosing for neovascular age-related macular degeneration using ranibizumab

Sohaib Riyaz Rufai; Hussein Almuhtaseb; Helena Lee; Richard Paul; Beth Stuart; Tony Kendrick; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3367. doi:

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

C-Reactive protein levels and the Outer retina in a large cohort study: UK Biobank

Real world outcomes for aflibercept in diabetic macula edema

Phenome-wide association analysis on risk variants for age-related macular degeneration reveals shared genetic influences with a wide range of disorders: the Million Veteran Program

Implementing digital applications for self-monitoring of visual function in the MONARCH study: technological and practical challenges.

Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma Levels Resulting in Increased Risk of Age-Related Macular Degeneration

Ambient Air Pollution Associations with Retinal Morphology in the UK Biobank

Long-term Outcome of Bevacizumab Therapy in Sorsby Fundus Dystrophy, A Case Series.

UK Multi-centre Medisoft EMR audit of intra-operative pressure event following implant of ILUVIEN ® (fluocinolone acetonide 190 μg).

The impact of prior steroid therapy on safety outcomes following treatment with ILUVIEN (fluocinolone acetonide) – An analysis of intra-ocular outcomes (IOP) from UK electronic medical records.

Twelve-Month Outcomes of Aflibercept vs. Ranibizumab for Wet Macular Degeneration

Twenty Four-Month Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration: Different Treatment Regimens in Year Two based on the Macular Status at the End of Year One

Identification of a Novel Variant Associated with anti-VEGF Response in Age-related Macular Degeneration Using Exome Chip Analysis

The myocilin GLN368Stop mutation in normal tension glaucoma

Hydroxyapatite induced experimental retinal degeneration in a murine model

Murine Retinal Development, Morphology and Function in Albinism: Potential Implications for Therapeutic Development

One year visual and anatomic outcomes in eyes receiving aflibercept according to a fixed-interval dosing (Q8W) for neovascular age-related macular degeneration.

2nd Year Visual Acuity Outcomes of AMD patients treated with Aflibercept : Data Analysis from the UK Aflibercept users group

Long term vision results following retinal gene therapy for choroideremia

Real-life outcomes of switching AntiVEGF treatment from ranibizumab to aflibercept for neovascular agerelated macular degeneration (nAMD): UK multicentre study.

A systematic review to assess the “Treat-and-Extend” dosing regimen compared to monthly and as-needed dosing for neovascular age-related macular degeneration using ranibizumab

To View More...

You must be signed into an individual account to use this feature.